Intellectual Property Protection

With the rise in outsourcing new drug and biologic development to overseas laboratories, how are biopharmaceutical executives protecting their intellectual property (IP) from insider theft?

Drug and biotech co-development projects are increasingly common as firms seek to increase their product pipelines and speed time to market. Smaller firms are at a distinct dis-advantage when it comes to negotiating agreements that protect their current intellectual property and their long-term creative potential.

Outside of the FDA regulated marketplace, one successful strategy to place co-development partners on equal footing and protect both partners' IP has been the creation of a Joint Development Agreement (JDA). Such a document can be created either during the initial negotiations or as a follow-on guiding set of principles incorporated as a contract amendment